The Price Gap in Numbers
Across the compounded telehealth market, tirzepatide commands a premium of roughly $50–$150 per month over semaglutide at the same provider. At some programs, the gap is as narrow as $25. At others, it exceeds $200. Here is a representative sample:
| Provider | Semaglutide | Tirzepatide | Monthly Premium |
|---|---|---|---|
| GobyMeds | $99 | $133 | +$34 |
| Gala | $179 | $179 | $0 (same flat rate) |
| Embody | $149 intro | Contact | Varies |
| Sunlight | $159 (intro) | $239 (intro) | +$80 |
| NovoCare (brand) | $349/mo | N/A | — |
| LillyDirect (brand) | N/A | $299–$449 | — |
The Clinical Case for Tirzepatide
Tirzepatide is a dual GIP/GLP-1 receptor agonist — it activates two hormonal pathways instead of one. The SURMOUNT clinical trial program demonstrated average weight loss of approximately 22% of body weight at the highest dose (15mg), compared to roughly 17% for semaglutide 2.4mg in the STEP trials. That five-percentage-point gap represents a meaningful clinical difference for many patients.
But averages obscure individual variation. Some patients respond better to semaglutide; others to tirzepatide. Your genetics, metabolic profile, starting weight, and adherence to lifestyle changes all influence which molecule delivers more for you.
💡 Clinical trial averages are population-level statistics. They predict trends, not your personal outcome. A 3–6 month trial of one medication is the only way to know which works better for your body.
The Cost-Per-Pound Framework
Rather than comparing monthly costs in isolation, consider the cost per pound of weight lost — a metric that accounts for both price and efficacy.
| Scenario | Starting Weight | Expected Loss | Lbs Lost | 12-Mo Cost | Cost/Lb |
|---|---|---|---|---|---|
| Semaglutide @ $179/mo | 220 lbs | ~17% | ~37 lbs | $2,148 | $58/lb |
| Tirzepatide @ $229/mo | 220 lbs | ~22% | ~48 lbs | $2,748 | $57/lb |
| Semaglutide @ $99/mo | 220 lbs | ~17% | ~37 lbs | $1,188 | $32/lb |
| Tirzepatide @ $133/mo | 220 lbs | ~22% | ~48 lbs | $1,596 | $33/lb |
At comparable providers, the cost per pound lost is nearly identical between the two medications. Tirzepatide costs more in absolute terms but delivers more weight loss, making the effective cost per unit of outcome roughly equivalent. The real savings come from choosing a competitive provider — not necessarily from choosing a specific molecule.
When Semaglutide Is the Better Value
- You are a strong semaglutide responder. If you are losing 20%+ body weight on semaglutide, the clinical premium of tirzepatide is marginal for you specifically.
- Your provider charges a large tirzepatide premium. At providers where tirz costs $150+/mo more, the cost-per-pound math tilts toward semaglutide.
- You prefer an established track record. Semaglutide has been on the market longer with more long-term safety data.
- You are needle-averse and oral options are cheaper. Oral semaglutide formulations are more widely available than oral tirzepatide at many compounding pharmacies.
When Tirzepatide Is Worth the Premium
- Your provider offers flat pricing for both. At providers like Gala where both medications cost the same, there is no price penalty for choosing the potentially more effective option.
- You have plateaued on semaglutide. Switching to a dual-agonist mechanism may restart weight loss when single-pathway therapy has stalled.
- The premium is small. At GobyMeds, the gap is just $34/month — $408 per year for a medication with higher average efficacy.
- You have significant weight to lose. For patients starting at higher BMIs, the incremental weight loss from tirzepatide can improve metabolic outcomes meaningfully — potentially reducing downstream healthcare costs that dwarf the medication premium.
The Oral Tirzepatide Option
A newer development in the market is compounded oral tirzepatide — tablets, troches, or sublingual drops that deliver tirzepatide without injections. This format is often priced competitively with injectable semaglutide, potentially giving you the dual-agonist mechanism at a single-agonist price point.
The trade-off is bioavailability: oral formulations are absorbed less efficiently than injectables, which prescribers account for in dosing. But for patients who are needle-averse, the format opens access to tirzepatide at a lower effective cost.
Decision Framework
Here is how to think about the semaglutide vs. tirzepatide question through a purely financial lens:
- Find your provider's price gap. What does each medication cost at your chosen (or prospective) provider?
- Calculate the annual premium. Multiply the monthly gap by 12. Is the annual premium under $500? Over $1,000?
- Assess your response. If you are already on semaglutide and losing weight steadily, the premium may not deliver proportional additional results for you.
- Consider oral formats. If tirzepatide's premium is steep in injectable form, check whether your provider offers a less expensive oral option.
- Discuss with your prescriber. This is ultimately a clinical decision informed by your metabolic profile, not just a pricing decision. Your prescriber can help weigh efficacy data against your specific health goals.
The Bottom Line
Tirzepatide's clinical premium is real but not universal. At competitive providers, the cost-per-pound-lost is nearly identical to semaglutide. At premium providers, the gap widens and the value proposition weakens. The smartest approach: choose a provider with competitive pricing on both medications, then let your clinician recommend the molecule based on your clinical profile — not your budget constraints.
⚠️ Compounded GLP-1 medications are not FDA-approved. They are prepared by licensed compounding pharmacies using FDA-approved active ingredients but are not individually reviewed by the FDA for safety, effectiveness, or quality. Always consult a licensed clinician before starting any GLP-1 therapy.